Enfortumab vedotin in the treatment of urothelial cancers and beyond.

Enfortumab vedotin (EV) is the first antibody-drug conjugate approved for locally advanced or metastatic urothelial cancers (la/mUCs), a disease group historically associated with limited prognosis and therapeutic options. EV consists of monomethyl auristatin E, a microtubule-disrupting agent linked to an antibody targeting Nectin-4. In clinical trials, EV demonstrated high response rates and superior survival in the third-line setting for la/mUC compared with chemotherapy. Peripheral neuropathy and rash were among the most common serious adverse events. EV is currently approved in multiple countries for the treatment of la/mUC in the later-line setting. Ongoing trials seek to expand the indication for EV and to study therapeutic combinations with other agents.

[1]  M. Galsky,et al.  Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. , 2022, European urology.

[2]  C. Rundle,et al.  Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin , 2022, The British journal of dermatology.

[3]  OUP accepted manuscript , 2022, The Oncologist.

[4]  G. Sonpavde,et al.  Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study , 2021, Cancer.

[5]  S. Jones,et al.  Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. , 2021, JAMA dermatology.

[6]  T. Powles,et al.  698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma , 2021, Annals of Oncology.

[7]  G. Sonpavde,et al.  Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. , 2021, Clinical genitourinary cancer.

[8]  A. Dobry,et al.  Cutaneous reactions with enfortumab vedotin: A case series and review of the literature , 2021, JAAD case reports.

[9]  Jianjun Gao,et al.  Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction , 2021, Frontiers in Oncology.

[10]  S. Chandarlapaty,et al.  Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.

[11]  B. Kelly,et al.  A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis , 2020, JAAD case reports.

[12]  R. Novoa,et al.  Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. , 2020, Journal of the American Academy of Dermatology.

[13]  M. Galsky,et al.  746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors , 2020 .

[14]  S. Aiba,et al.  Severe eczematoid and lichenoid eruption with full‐thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin , 2020, The Journal of dermatology.

[15]  M. Milowsky,et al.  EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma , 2019, Annals of Oncology.

[16]  M. Uemura,et al.  A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma , 2019, Investigational New Drugs.

[17]  G. Sonpavde,et al.  Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC) , 2016 .

[18]  S. Theurich,et al.  Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity , 2014, Oncoimmunology.

[19]  S. Barni,et al.  Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. , 2014, European urology.

[20]  M. Jewett,et al.  A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. , 2012, The Journal of urology.

[21]  Jun Miyoshi,et al.  Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation , 2008, Nature Reviews Molecular Cell Biology.